“On the other hand, participating in a combo tri
Post# of 148172
This is actually false. Remdesevir is unfortunately the SOC and the trial would’ve consisted of two arms, LL/remdesevir compared to remdesevir (the SOC). Therefore, the benefit of leronlimab would’ve been very clear and added to the growing science that leronlimab may be a monotherapy for the S/C population.